TC
PLXP

TFS Capital’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

TFS Capital’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,346
Closed -$156K – 932
2016
Q3 		$156K Buy
+1,346
New +$131K 0.04% 594

Other funds holding PLXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MC
Middleton & Co Boston, Massachusetts $877M AUM 15.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TFS Capital's PLXP Position: Q4 2016 in Review

TFS Capital sold out of PLx Pharma Inc. Common Stock (PLXP) in Q4 2016, closing a stake of 1,346 shares — an estimated $156K sold.

TFS Capital first reported a position in PLXP in Q3 2016 and held it in 1 quarter. The position peaked at $156K in Q3 2016. 19 funds tracked by Wall St. Rank hold PLXP as of Q4 2016.

  • TFS Capital reported no remaining PLx Pharma Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 1,346 PLx Pharma Inc. Common Stock shares in Q4 2016, an estimated $156K.
  • TFS Capital first reported a position in PLx Pharma Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • TFS Capital's PLx Pharma Inc. Common Stock position peaked at $156K in Q3 2016.
  • 19 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.